Core Insights - Mainz Biomed N.V. announced its participation in the 2025 Maxim Growth Summit, scheduled for October 22-23, 2025, at The Hard Rock Hotel NYC [1] - The summit will feature industry leaders and discussions on various sectors, including biotechnology and artificial intelligence [2] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for early cancer detection, with its flagship product, ColoAlert, aimed at colorectal cancer [4] - The company is conducting the eAArly DETECT 2 clinical study in preparation for a pivotal FDA study for U.S. regulatory approval [4] - Mainz Biomed's product portfolio also includes PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection [4] Event Participation - During the Maxim Growth Summit, Mainz Biomed will engage in one-on-one meetings with institutional investors and senior analysts from Maxim [3]